- Home
- KURA vs TLRY Comparison
KURA vs TLRY Comparison
Compare KURA & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- TLRY
- Stock Information
- Founded
- KURA 2014
- TLRY N/A
- Country
- KURA United States
- TLRY Canada
- Employees
- KURA N/A
- TLRY N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- TLRY Medicinal Chemicals and Botanical Products
- Sector
- KURA Health Care
- TLRY Health Care
- Exchange
- KURA Nasdaq
- TLRY Nasdaq
- Market Cap
- KURA 793.2M
- TLRY 1.3B
- IPO Year
- KURA N/A
- TLRY 2018
- Fundamental
- Price
- KURA $7.26
- TLRY $1.18
- Analyst Decision
- KURA Strong Buy
- TLRY Hold
- Analyst Count
- KURA 11
- TLRY 3
- Target Price
- KURA $27.89
- TLRY $1.88
- AVG Volume (30 Days)
- KURA 1.8M
- TLRY 42.2M
- Earning Date
- KURA 02-25-2025
- TLRY 01-10-2025
- Dividend Yield
- KURA N/A
- TLRY N/A
- EPS Growth
- KURA N/A
- TLRY N/A
- EPS
- KURA N/A
- TLRY N/A
- Revenue
- KURA N/A
- TLRY $829,216,000.00
- Revenue This Year
- KURA N/A
- TLRY $16.98
- Revenue Next Year
- KURA $233.30
- TLRY $5.96
- P/E Ratio
- KURA N/A
- TLRY N/A
- Revenue Growth
- KURA N/A
- TLRY 18.38
- 52 Week Low
- KURA $6.98
- TLRY $1.14
- 52 Week High
- KURA $24.17
- TLRY $2.97
- Technical
- Relative Strength Index (RSI)
- KURA 17.38
- TLRY 39.02
- Support Level
- KURA $6.98
- TLRY $1.40
- Resistance Level
- KURA $8.88
- TLRY $1.51
- Average True Range (ATR)
- KURA 0.33
- TLRY 0.10
- MACD
- KURA 0.05
- TLRY -0.02
- Stochastic Oscillator
- KURA 13.40
- TLRY 7.89
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.